Nephrology · KIMS Secunderabad
Analgesic Nephropathy — When Painkillers Silently Damage the Kidneys
Analgesic nephropathy is one of the most common, most preventable, and most underrecognised causes of chronic kidney disease in India. It results from the long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) — ibuprofen, diclofenac, naproxen, aspirin in analgesic doses, indomethacin, and combinations — causing progressive damage to the renal medulla (papillary necrosis) and the interstitium (chronic interstitial nephritis). The damage accumulates silently over years: the patient continues taking painkillers without symptoms until kidney function has declined significantly.
In India, NSAIDs are widely available over the counter. Self-medication with diclofenac, ibuprofen, and combination analgesic tablets for back pain, joint pain, menstrual pain, and headaches — often in doses and frequencies that exceed the recommended limits — is extremely common. Many patients take these medications daily for years without any monitoring of kidney function, unaware that the cumulative dose is progressively destroying their renal papillae. By the time analgesic nephropathy is diagnosed, significant and irreversible CKD may already have developed.
How NSAIDs damage the kidneys
Prostaglandin inhibition — the central mechanism
The renal medulla operates in an environment of low oxygen tension, high osmolality, and poor blood supply. Prostaglandins (PGE2 and PGI2) — produced locally within the medullary interstitium — maintain medullary blood flow by counterbalancing the intense vasoconstriction of the vasa recta capillaries from angiotensin II and sympathetic stimulation. NSAIDs inhibit cyclooxygenase (COX-1 and COX-2) — the enzyme that produces prostaglandins — removing this vasodilatory protection. Medullary blood flow falls, tubular cells become ischaemic, and the vasa recta supplying the papillary tips may thrombose.
Papillary necrosis
Ischaemic death of the renal papillae — the apices of the medullary pyramids. The necrotic papillae slough off into the collecting system, sometimes causing visible haematuria, passage of necrotic tissue in the urine (papillary sloughing), and ureteric obstruction (from a sloughed papilla obstructing the ureter — mimicking a stone on imaging). Papillary necrosis is the pathological hallmark of analgesic nephropathy.
Chronic interstitial nephritis
The inflammatory response to papillary necrosis extends into the surrounding medullary interstitium, causing progressive interstitial fibrosis and tubular atrophy — the pathological substrate of CKD. This process continues even after NSAIDs are stopped, because the established fibrosis does not reverse.
Who is at highest risk
Patients taking daily NSAIDs for more than 2 years — chronic musculoskeletal pain, rheumatoid arthritis managed with regular NSAIDs without kidney monitoring.
Patients taking combination analgesic preparations — particularly those containing aspirin + paracetamol + codeine combinations, which historically (in the phenacetin era) caused the most severe analgesic nephropathy.
Women above 45 — historically, analgesic nephropathy has been more common in women who self-medicate for musculoskeletal and menstrual pain.
Pre-existing CKD — any degree of reduced kidney function amplifies NSAID nephrotoxicity, because prostaglandins are most important for maintaining GFR when renal perfusion is already compromised.
Concurrent dehydration — NSAID use during any illness causing dehydration, vomiting, diarrhoea, or fever dramatically increases the risk of acute-on-chronic kidney injury.
Diabetes and hypertension — amplify the NSAID-related reduction in renal prostaglandins through their own mechanisms of impaired renal vasodilation.
Clinical features and diagnosis
Slowly progressive CKD
Often entirely asymptomatic until eGFR falls below 30 ml/min. Detected only on routine blood tests.
Polyuria and nocturia
From impaired tubular concentrating ability (papillary necrosis destroys the countercurrent mechanism in the medullary pyramids).
Recurrent UTIs
Stagnant urine in calyces above necrotic papillae is prone to infection.
Haematuria
From papillary sloughing or secondary to UTI.
Hypertension
Develops as CKD progresses.
CT KUB
Papillary necrosis appears as filling defects in the renal calyces (the outlines of necrotic papillae) and medullary calcifications (calcification of necrotic papillary tissue). These are characteristic CT findings that confirm the diagnosis in the appropriate clinical context.
Renal ultrasound
Echogenic medullary pyramids, irregular calyceal outlines, and shrunken kidneys with irregular outlines in advanced analgesic nephropathy.
Treatment and prevention
Stop all NSAIDs — the most important intervention
Complete cessation of all NSAIDs and analgesic combinations halts further papillary damage. Kidney function may stabilise (if not too much damage has already occurred) but the established CKD does not reverse. Alternative pain management: paracetamol in standard doses (safe for the kidneys at recommended doses — below 3g/day in CKD patients), topical NSAIDs (much lower systemic absorption and renal exposure), tramadol or low-dose opioids for severe pain under medical supervision.
CKD management
Standard CKD management protocol at KIMS: ACE inhibitor or ARB for proteinuria reduction and blood pressure control, SGLT2 inhibitor, annual urine ACR and eGFR monitoring, dietary protein moderation.
Patient education
The most impactful long-term intervention. Many patients with analgesic nephropathy are unaware that their painkillers are damaging their kidneys. At KIMS, all patients with analgesic nephropathy receive explicit counselling — with information on which drugs to avoid, safe alternatives, and the importance of kidney monitoring for life.
The average Indian patient with analgesic nephropathy has been taking NSAIDs daily for 5 to 10 years before the diagnosis is made. The kidneys have been silently deteriorating throughout. Kidney function that cannot be recovered — papillary necrosis and interstitial fibrosis once established are permanent. The critical message: check kidney function with a blood test (creatinine and eGFR) if you take NSAIDs regularly — and stop if the kidneys are already affected.
Book a Kidney Health Check at KIMS if You Take Regular Painkillers
Frequently Asked Questions — Analgesic Nephropathy
Yes — long-term or excessive use of ibuprofen (and other NSAIDs including diclofenac, naproxen, and aspirin in analgesic doses) causes kidney damage through two mechanisms: acute vasoconstriction (reducing renal blood flow, causing acute kidney injury — particularly during any episode of dehydration) and chronic papillary necrosis (progressive destruction of the renal papillae from chronic prostaglandin inhibition). Occasional use of ibuprofen at recommended doses in a healthy person with normal kidney function carries very low risk. Daily use for weeks, months, or years — particularly in anyone with pre-existing CKD, diabetes, hypertension, or regular dehydration — is harmful.
Paracetamol, at recommended doses (below 2 to 3 grams per day in patients with CKD, below 4 grams per day in those with normal kidney function), does not cause the same prostaglandin-mediated kidney damage as NSAIDs and is the preferred analgesic for patients with CKD. However, paracetamol overdose is acutely toxic to both the liver and the kidneys. And historically, analgesic combinations containing phenacetin (now withdrawn from the market) were strongly associated with analgesic nephropathy — paracetamol alone does not carry this risk at standard doses. Paracetamol is the safe painkiller of choice for patients with kidney disease.
Acute kidney injury from NSAIDs can occur within days — particularly during any episode of volume depletion (diarrhoea, vomiting, fever, excessive sweating) when the kidney's adaptive response depends critically on prostaglandin-mediated vasodilation that NSAIDs remove. Chronic analgesic nephropathy from long-term use develops over years — papillary necrosis accumulates with cumulative dose and duration of NSAID use. Studies show that regular use for 2 or more years with a cumulative intake of 1,000 or more tablets significantly increases the risk. The exact threshold varies by individual susceptibility — patients with pre-existing CKD, diabetes, or hypertension develop damage at lower cumulative doses.
Partially — stopping NSAIDs halts further papillary damage and prevents acute-on-chronic episodes. Kidney function may stabilise or modestly improve as residual inflammation resolves. However, the papillary necrosis (dead renal papillae) and the interstitial fibrosis that has accumulated do not reverse — the CKD caused by analgesic nephropathy is permanent at the stage it has reached when the drugs are stopped. This is why early detection and early cessation give the best outcome: a patient who stops NSAIDs at eGFR 50 will do significantly better than one who stops at eGFR 20.
KIMS Secunderabad — Dr. V. S. Reddy (HOD - Nephrology & Transplant Physician, 20+ years), CT KUB for papillary necrosis diagnosis, eGFR and ACR monitoring, NSAID cessation counselling, alternative pain management planning, CKD management including ACE inhibitor and SGLT2 inhibitor protocol, transplant evaluation for advanced CKD. NABH and NABL accredited. Call 040-4488-5000.